TMO 10-K Analysis: The Three-Layer Debt Subsidy Behind 32.6× Earnings
Thermo Fisher Scientific generated $44.6 billion in revenue in FY2025 and grew EPS 7.3% to $17.74. But free cash flow declined 13.4% to $6.29 billion. At 32.6× trailing earnings, the market embeds roughly $50 billion of enterprise value in TMO's ability to keep acquiring its way to growth. The 10-K reveals three hidden subsidies — $283 million in interest rate swap benefits, $16 billion in sub-3% legacy bonds repricing higher, and a declining amortization tailwind — propping up the earnings narrative while $14 billion in near-term obligations come due.